Houston company receives $1.5M grant for urine test to combat opioid crisis


Houston-based BreviTest Technologies received a $ 1.5 million grant to commercialize a urine test, which helps determine whether someone has been misused or addicted to opioid prescriptions.

Tissue box-sized devices can determine the amount of opioid that a patient takes within 10 to 15 minutes.

Michael Heffernan, director of product development at BreviTest, said, “This helps doctors better understand what patients have been taking recently.” "I want to be able to match what patients are saying."

Related: HCA Houston area, opioid recovery day & # 39; crisis crisis & # 39;

If a patient claims to take medicine, but the urine sample does not contain opioids, there may be a concern that an individual is selling prescription drugs.


According to the Centers for Disease Control and Prevention, opioids died in 47,600 overdose in 2017. Urine drug testing is one of the guidelines of government agencies for prescribing opioids in a safe way, but for doctors who do not have an in-house laboratory, current techniques can take days. It can be a painful delay for people who are uncomfortable for patients and actually suffer from chronic pain. This has led doctors to rarely use urine drug tests, Heffernan said.

BreviTest, created by Fannin Innovation Studio, hopes to be the solution. The organization will continue to develop devices using grants from the National Drug Abuse Institute, along with funding from Small Business Innovation Research Phase II grants.

LEAVE A REPLY

Please enter your comment!
Please enter your name here